View Older Stories View More Recent Stories

May 17, 2018 08:30AM Navitor Pharmaceuticals to Present at UBS Global Healthcare Conference
May 16, 2018 07:30AM Plastiq Secures $27 Million in New Funding Round to Accelerate Growth of Payments Platform for Small Business
May 15, 2018 05:00AM Rodin Therapeutics Expands Leadership Team, Adding Extensive Experience in Clinical and Business Development
May 10, 2018 09:11PM Form 4 Carbon Black, Inc. For: May 08 Filed by: ATLAS VENTURE ENTREPRENEURS FUND VI LP
May 8, 2018 09:54AM Form 13F-HR Atlas Venture Associates For: Mar 31
May 8, 2018 08:00AM Generation Bio Expands Leadership Team with Appointment of Sara Den Besten as Head of Human Resources
May 4, 2018 10:00AM Science 2 Startup Symposium Convened Over 230 Academic Researchers, Venture Capitalists, Entrepreneurs, and Pharmaceutical Executives, Creating Connections that can Advance Scientific Innovation and E
May 3, 2018 09:52PM Form 3 Carbon Black, Inc. For: May 03 Filed by: ATLAS VENTURE ENTREPRENEURS FUND VI LP
May 1, 2018 08:00AM Obsidian to Present Data on Regulated Cytokine Programs at the Upcoming American Society of Gene and Cell Therapy (ASGCT) 21st Annual Meeting
Apr 23, 2018 04:19PM Form 4 Atlas Venture Associates For: Apr 23 Filed by: Surface Oncology, Inc.
Apr 18, 2018 04:56PM Form 3 Atlas Venture Associates For: Apr 18 Filed by: Surface Oncology, Inc.
Apr 17, 2018 08:00AM Obsidian Therapeutics Presents Preclinical Data from Regulated Cytokine Programs that Enable CAR-T Therapies with Controllable Functions
Apr 12, 2018 09:00AM Atlas Venture, F-Prime Capital Partners and SV Health Investors to Host Symposium Featuring Therapeutics Startup Ideas From World’s Top Academic Research Institutions
Apr 9, 2018 09:30AM Be The Match BioTherapies Strengthens Partnership with Magenta Therapeutics
Apr 9, 2018 09:00AM Magenta Therapeutics Secures $52 Million in Series C Financing
Apr 9, 2018 08:00AM Generation Bio Strengthens Leadership Team with Appointment of Will McCarthy as Chief Business Officer and Jennifer Elliott, Ph.D., J.D., as Head of Legal Affairs and Intellectual Property
Apr 6, 2018 10:05AM Magenta Therapeutics Appoints Amy Ronneberg, President of Be The Match BioTherapies, to Board of Directors
Apr 5, 2018 08:30AM Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic Disorders
Apr 3, 2018 05:18PM Form 4 Atlas Venture Associates For: Apr 03 Filed by: Unum Therapeutics Inc.
Apr 3, 2018 08:30AM Magenta Therapeutics Announces Departure of Chief Operating Officer Bastiano Sanna, Ph.D.
Mar 28, 2018 09:11PM Form 3 Unum Therapeutics, Inc. For: Mar 28 Filed by: Atlas Venture Associates IX, L.P.
Mar 20, 2018 07:00AM Surface Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of SRF231
Mar 19, 2018 08:30AM Obsidian Therapeutics to Present at Upcoming Investor Conferences
Mar 15, 2018 08:00AM Obsidian to Present Data on its Destabilizing Domain Technology and Product Programs at the Upcoming 2018 American Association for Cancer Research (AACR) Annual Meeting
Mar 14, 2018 04:31PM Form SC 13D Spero Therapeutics, Inc. Filed by: Atlas Venture Fund X, L.P.
Mar 12, 2018 08:00AM Precision Neuroscience Company Cadent Therapeutics Initiates Phase 1 Study of Lead Compound CAD-1883
Mar 8, 2018 09:00AM Magenta Therapeutics Strengthens Leadership Team with Promotions, New Hires
Mar 6, 2018 08:00AM Disarm Therapeutics Expands Scientific Advisory Board with Experts in Neurology, Neuropathy, and Axonal Degeneration
Feb 27, 2018 07:00AM Generation Bio Announces $100 Million Series B Financing to Advance GeneWave™ Platform for Re-Dosable Gene Therapy
Feb 22, 2018 07:00AM Surface Oncology Expands Board of Directors
Feb 21, 2018 09:12AM Magenta Therapeutics Hires John Davis, MD, MPH, as Chief Medical Officer
Feb 13, 2018 11:04AM Form SC 13G Spero Therapeutics, Inc. Filed by: Atlas Venture Associates IX, L.P.
Feb 13, 2018 08:00AM Obsidian Therapeutics Presents Data Demonstrating Regulation of Protein Activity with its Next-Generation CAR-T Platform at Keystone Symposium on Emerging Cellular Therapies
Feb 12, 2018 07:00AM Surface Oncology Promotes Jeff Goater to Chief Executive Officer
Feb 12, 2018 06:54AM Form SC 13G/A ZAFGEN, INC. Filed by: Atlas Venture Fund VII L P
Feb 12, 2018 06:54AM Form SC 13G/A Egalet Corp Filed by: Atlas Venture Fund VII L P
Feb 12, 2018 06:54AM Form SC 13G/A Intellia Therapeutics, Filed by: Atlas Venture Fund IX, L.P.
Feb 6, 2018 06:55AM Atlas Venture Announces That Nessan Bermingham Re-Joins as Venture Partner
Feb 5, 2018 04:25PM Form 13F-HR Atlas Venture Associates For: Dec 31
Feb 1, 2018 07:00AM AVROBIO, Inc. Announces $60 Million Series B Financing to Advance Gene Therapy Pipeline for Lysosomal Storage Disorders and Apply Lentiviral Platform to Other Genetic Diseases
Jan 23, 2018 08:00AM Disarm Therapeutics Appoints Thomas Engber as Senior Vice President, Head of Neuropharmacology and Translational Sciences
Jan 22, 2018 08:00AM Harbour BioMed Completes Series A+ Round Financing to Accelerate the Development of Clinical Programs and Company Growth
Jan 8, 2018 01:10PM Vaccinex, Inc. Announces Research Collaboration Employing ActivMAb® Platform Technology and Antibody License Option Agreement with Surface Oncology
Jan 4, 2018 07:00AM Atlas Venture Launches Generation Bio
Dec 19, 2017 09:00AM Disarm Therapeutics Appoints Peter Keller Chief Business Officer
Dec 14, 2017 06:00AM Kyn Therapeutics Announces $49 Million Series A Capital Available to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways
Dec 6, 2017 06:15AM Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products
Nov 15, 2017 07:00AM Navitor Pharmaceuticals to Develop NV-5138, a Specific Activator of mTORC1 for Treatment-Resistant Depression, Based on Promising Data Presented at Society for Neuroscience 2017
Nov 9, 2017 02:10PM Navitor Pharmaceuticals’ Scientific Founder Makes Seminal Discoveries Related to Role of Nutrient Sensors in mTOR Regulation and Activity
Nov 3, 2017 09:14AM Form 13F-HR Atlas Venture Associates For: Sep 30
View More Recent Stories View Older Stories